A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Inclusion Criteria: * Adult patients,\>/= 18 years of age * Histological/cytological confirmation of colorectal or breast cancer * Patient is ambulatory and has a Karnofsky performance status of \> 70% * Body surface area between 1.5 and 2.0 m2 * Either: * Due to receive Xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or * Currently receiving Xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on Day 1 and Day 2 Exclusion Criteria: * Any contraindication to Xeloda * Received Xeloda in the 6 days prior to Day 1 * Subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy) * Renal impairment * Pregnant or lactating females * Participation in an investigational drug study within 28 days prior to screening * Lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome * Serious uncontrolled intercurrent infections * History of clinically significant coronary artery disease * Concomitant treatment with warfarin * Known dihydropyrimidine dehydrogenase deficiency